These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 12397516)

  • 21. Prospective study of patients' subjective responses to botulinum toxin injection for spasmodic dysphonia.
    Liu TC; Irish JC; Adams SG; Durkin LC; Hunt EJ
    J Otolaryngol; 1996 Apr; 25(2):66-74. PubMed ID: 8683655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings.
    Zwirner P; Murry T; Swenson M; Woodson GE
    Laryngoscope; 1992 Apr; 102(4):400-6. PubMed ID: 1556889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin injection for adductor spastic dysphonia: patient self-ratings of voice and phonatory effort after three successive injections.
    Aronson AE; McCaffrey TV; Litchy WJ; Lipton RJ
    Laryngoscope; 1993 Jun; 103(6):683-92. PubMed ID: 8502104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Voice handicap index results for older patients with adductor spasmodic dysphonia.
    Wingate JM; Ruddy BH; Lundy DS; Lehman J; Casiano R; Collins SP; Woodson GE; Sapienza C
    J Voice; 2005 Mar; 19(1):124-31. PubMed ID: 15766857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia.
    Roy N; Mauszycki SC; Merrill RM; Gouse M; Smith ME
    Folia Phoniatr Logop; 2007; 59(2):83-90. PubMed ID: 17337898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report.
    Rontal M; Rontal E; Rolnick M; Merson R; Silverman B; Truong DD
    Laryngoscope; 1991 Aug; 101(8):911-4. PubMed ID: 1865744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia.
    Vasconcelos S; Birkent H; Sardesai MG; Merati AL; Hillel AD
    Laryngoscope; 2009 Oct; 119(10):2004-7. PubMed ID: 19572275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia.
    Damrose JF; Goldman SN; Groessl EJ; Orloff LA
    J Voice; 2004 Sep; 18(3):415-22. PubMed ID: 15331116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin therapy for abductor spasmodic dysphonia.
    Woodson G; Hochstetler H; Murry T
    J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
    Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
    Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a portable, audible-only electromyography device in the treatment of spasmodic dysphonia.
    Jeffcoat BT; Schweinfurth JM
    Laryngoscope; 2008 May; 118(5):942-3. PubMed ID: 18197130
    [No Abstract]   [Full Text] [Related]  

  • 33. Adductor spasmodic dysphonia and botulinum toxin treatment: the effect on well-being.
    Langeveld TP; Luteijn F; van Rossum M; Drost HA; Baatenburg de Jong RJ
    Ann Otol Rhinol Laryngol; 2001 Oct; 110(10):941-5. PubMed ID: 11642427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A.
    Weber A; Heger S; Sinkgraven R; Heckmann M; Elsner P; Rzany B
    Br J Dermatol; 2005 Feb; 152(2):342-5. PubMed ID: 15727649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia.
    Wong DL; Adams SG; Irish JC; Durkin LC; Hunt EJ; Charlton MP
    J Otolaryngol; 1995 Aug; 24(4):209-16. PubMed ID: 8551532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin A prolongs functional durability of voice prostheses in laryngectomees with pharyngoesophageal spasm.
    Krause E; Hempel JM; Gürkov R
    Am J Otolaryngol; 2009; 30(6):371-5. PubMed ID: 19880024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia.
    Wong DL; Irish JC; Adams SG; Durkin LC; Hunt EJ
    J Otolaryngol; 1995 Feb; 24(1):64-8. PubMed ID: 7769649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
    Chang CY; Chabot P; Walz CM
    Ear Nose Throat J; 2009 May; 88(5):E18. PubMed ID: 19444777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Thompson AR
    J Ark Med Soc; 1994 Jan; 90(8):383-5. PubMed ID: 8175618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia.
    Zwirner P; Murry T; Woodson GE
    Eur Arch Otorhinolaryngol; 1997; 254(8):391-5. PubMed ID: 9332896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.